HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

ODTX — Odyssey Therapeutics Inc.

ODTX (Odyssey Therapeutics Inc.) stock: $19.23, $924.3M market cap, $387.0M cash, $537.3M EV, $1.08B fully diluted market cap. Lead program: OD-07656 (Ulcerative Colitis (UC)), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

Odyssey Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology.

Source: 10-Q FY2026 via SEC EDGAR

Share price
$19.23
Market cap
$924.3M
Cash
$387.0M
Enterprise value
$537.3M

Balance sheet

Cash$387.0M
Debt$0.0M
Net cash$387.0M
Enterprise value$537.3M
Basic shares48.1M shares
Fully diluted shares56.4M shares
Fully diluted market cap$1,084.7M
Cash per share$8.05
Quarterly burn$34.5M
Cash runway12.5 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common
47.9M
Pre-funded warrants
0.0M
Options
7.9M
RSUs
0.1M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.5M
FDSO
56.4M

Cap table as of 2026-06-30.

Price history

Loading ODTX daily closes…

Loading price history…

Next catalyst

OD-001 · Est. Sep 30, 2027 · half midpoint · guided in 8 mo

Recently reported

Vedolizumab Phase 2 Negative · 2026-10-20
OD-001 · ulcerative colitis (uc), uc - ulcerative colitis
Primary: Change from baseline in modified Mayo score at the end of induction at Week 12 — mean reduction of 2.4 points across the evaluable population; p<0.001
· Clinical remission, clinical response, and symptomatic remission at Week 12 were 27%, 61%, and 49%, respectively, in the pooled 20 mg BID group (n=41)
· Clinical remission, clinical response, and symptomatic remission at Week 12 were 20%, 40%, and 27%, respectively, at 10 mg BID (n=15)
· Clinical remission at 20 mg BID was 29% in advanced therapy-naive patients (n=28) and 23% in advanced therapy-experienced patients (n=13)
· Clinical remission at Week 12 for patients taking OD-001 at 20 mg BID was 16% in patients with a Mayo Endoscopic Score (MES) of 3 (n=19)
· Symptomatic remission at 20 mg BID reached 21% at Week 2, increasing throughout the induction period with no plateau observed through Week 12
· Open-label, dose-ranging trial with no concurrent placebo control; completed induction analysis comprises all 56 efficacy-evaluable patients (NCT06850727)
Safety: Generally well tolerated during the 12-week induction period, with no serious adverse events, serious infections, treatment-related discontinuations, or treatment-emergent liver function abnormalities; three adverse events in the 20 mg BID group were considered drug-related (two fevers and one headache)
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego